Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split – Wall Street Journal

Palatin Tech To Cut Work Force In Half, Do Reverse Stock Split
Wall Street Journal
Palatin has been developing bremelanotide for male and female sexual dysfunction and PL-3994 for acute severe asthma. The company plans to submit plans for
Palatin Announces Strategic Realignment of OperationsPR Newswire (press release)
Palatin Reducing Workforce By 50%; To Effect 1-for-10 Reverse Stock Split RTT News

all 17 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *